PTEN, a tumor suppressor that inhibits the PI3K/Akt pathway, has been extensively reported to counteract tumor growth in cancers of the endometrium, brain, skin, and prostate (Martini et al., 2014; Danielsen et al., 2015). Here, AKT1 is linked to neoplasm.